Cholesteryl ester transfer protein inhibitors (CETPi) entered clinical trials with a seemingly solid biological hypothesis and great clinical promise. This class of drugs raises high-density lipoprotein (HDL), the so-called “good cholesterol”. However, clinical development for this class has now been almost entirely abandoned. The dashboard below provides a set of tools to examine this entire portfolio of research. The "AERO graph" tab depicts the developmental trajectories for each CETPi. The "Histogram" tab shows the number of completed trials by phase each year. The "Outcome Matrix" tab summarizes the quality of evidence for each primary outcome. The "Data Table" tab shows the data underlying these visualizations.
What does this show?
Clinical trials are never isolated experiments. They always exist within some larger body of evidence. The same is true for drug development programs. Each developmental trajectory is embedded within the larger portfolio of the drug class, mechanism, and disease. Understanding what we know about a portfolio, and making good decisions about where are the knowledge gaps and development opportunities, requires a lot of data and many different lenses through which to examine that data. That is what this kind of dashboard is designed to supply—a comprehensive overview of the research landscape.